Buspirone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Buspirone" in English language version.

refsWebsite

Global rank English rank

42nih.gov

4^th place

36doi.org

2^nd place

24semanticscholar.org

11^th place

8^th place

8books.google.com

3^rd place

5espacenet.com

800^th place

676^th place

4drugs.com

399^th place

333^rd place

3web.archive.org

1^st place

2clincalc.com

3,912^th place

2,496^th place

2worldcat.org

5^th place

2fda.gov

447^th place

338^th place

1in.gov.br

3,151^st place

5,932^nd place

1medscape.com

719^th place

636^th place

1zenodo.org

621^st place

380^th place

1tga.gov.au

3,984^th place

2,622^nd place

1medicines.org.uk

3,823^rd place

2,387^th place

1archive.org

6^th place

1unc.edu

1,538^th place

1,042^nd place

1harvard.edu

18^th place

17^th place

1patents.google.com

1,182^nd place

725^th place

1federalregister.gov

2,474^th place

1,469^th place

archive.org

Geddes J, Gelder MG, Mayou R (2005). Psychiatry. Oxford [Oxfordshire]: Oxford University Press. p. 237. ISBN 978-0-19-852863-0.

books.google.com

Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 192–. ISBN 978-1-4757-2085-3.
Schatzberg AF, Nemeroff CB (2009). The American Psychiatric Publishing Textbook of Psychopharmacology. American Psychiatric Pub. pp. 490–. ISBN 978-1-58562-309-9.
Sadock BJ, Sadock VA, Ruiz P (22 September 2014). Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Wolters Kluwer Health. pp. 3211–. ISBN 978-1-4698-8375-5.
Dart RC (2004). Medical Toxicology. Lippincott Williams & Wilkins. pp. 886–. ISBN 978-0-7817-2845-4.
Stern TA, Fava M, Wilens TE, Rosenbaum JF (27 April 2015). Massachusetts General Hospital Psychopharmacology and Neurotherapeutics E-Book. Elsevier Health Sciences. pp. 29–. ISBN 978-0-323-41323-7.
Nutt DJ, Ballenger JC (15 April 2008). Anxiety Disorders. John Wiley & Sons. pp. 395–. ISBN 978-0-470-98683-7.
Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 149–. ISBN 978-3-88763-075-1.
Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 57–. ISBN 978-94-011-4439-1.

clincalc.com

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Buspirone - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

doi.org

Loane C, Politis M (June 2012). "Buspirone: what is it all about?". Brain Research. 1461: 111–118. doi:10.1016/j.brainres.2012.04.032. PMID 22608068. S2CID 11734819.
Gammans RE, Mayol RF, LaBudde JA (March 1986). "Metabolism and disposition of buspirone". The American Journal of Medicine. 80 (3B): 41–51. doi:10.1016/0002-9343(86)90331-1. PMID 3515929.
Wong H, Dockens RC, Pajor L, Yeola S, Grace JE, Stark AD, et al. (August 2007). "6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats". Drug Metabolism and Disposition. 35 (8): 1387–1392. doi:10.1124/dmd.107.015768. PMID 17494642. S2CID 25558546.
Mahmood I, Sahajwalla C (April 1999). "Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug". Clinical Pharmacokinetics. 36 (4): 277–287. doi:10.2165/00003088-199936040-00003. PMID 10320950. S2CID 1102318.
Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, et al. (April 2005). "Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes". Drug Metabolism and Disposition. 33 (4): 500–507. doi:10.1124/dmd.104.000836. PMID 15640381. S2CID 10142905.
Howland RH (November 2015). "Buspirone: Back to the Future". Journal of Psychosocial Nursing and Mental Health Services. 53 (11): 21–24. doi:10.3928/02793695-20151022-01. PMID 26535760.
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clinic Proceedings. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.
Trinchieri M, Trinchieri M, Perletti G, Magri V, Stamatiou K, Cai T, et al. (August 2021). "Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review". The Journal of Sexual Medicine. 18 (8): 1354–1363. doi:10.1016/j.jsxm.2021.05.016. PMID 34247952. S2CID 235798526. Buspirone, a non-benzodiazepine anxiolytic, have even demonstrated enhancement of sexual function in certain individuals. For this reason, they have been proposed as augmentation agents (antidotes) or substitution agents in patients with emerging sexual dysfunction after treatment with antidepressants.
Montejo AL, Prieto N, de Alarcón R, Casado-Espada N, de la Iglesia J, Montejo L (October 2019). "Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach". Journal of Clinical Medicine. 8 (10): 1640. doi:10.3390/jcm8101640. PMC 6832699. PMID 31591339.
Garrett AR, Hawley JS (April 2018). "SSRI-associated bruxism: A systematic review of published case reports". Neurology. Clinical Practice. 8 (2): 135–141. doi:10.1212/CPJ.0000000000000433. PMC 5914744. PMID 29708207.
Prisco V, Iannaccone T, Di Grezia G (1 April 2017). "Use of buspirone in selective serotonin reuptake inhibitor-induced sleep bruxism". European Psychiatry. Abstract of the 25th European Congress of Psychiatry. 41: S855. doi:10.1016/j.eurpsy.2017.01.1701. S2CID 148816505.
Fulton B, Brogden RN (1997). "Buspirone". CNS Drugs. 7 (1): 68–88. doi:10.2165/00023210-199707010-00007. ISSN 1172-7047. S2CID 57668523.
Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ (December 1998). "Grapefruit juice substantially increases plasma concentrations of buspirone". Clinical Pharmacology and Therapeutics. 64 (6): 655–660. doi:10.1016/S0009-9236(98)90056-X. PMID 9871430. S2CID 22009095.
Lamberg TS, Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ (1998). "The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone". European Journal of Clinical Pharmacology. 54 (9–10): 761–766. doi:10.1007/s002280050548. PMID 9923581. S2CID 21939719.
Boess FG, Martin IL (1994). "Molecular biology of 5-HT receptors". Neuropharmacology. 33 (3–4): 275–317. doi:10.1016/0028-3908(94)90059-0. PMID 7984267. S2CID 35553281.
Sato H, Skelin I, Diksic M (July 2010). "Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study". Brain Research. 1345: 28–44. doi:10.1016/j.brainres.2010.05.054. PMID 20501324. S2CID 22979155.
Hamik A, Oksenberg D, Fischette C, Peroutka SJ (July 1990). "Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites". Biological Psychiatry. 28 (2): 99–109. doi:10.1016/0006-3223(90)90627-e. PMID 1974152. S2CID 25608914.
Peroutka SJ, Switzer JA, Hamik A (1989). "Identification of 5-hydroxytryptamine1D binding sites in human brain membranes". Synapse. 3 (1): 61–66. doi:10.1002/syn.890030109. PMID 2521959. S2CID 23503235.
Waeber C, Schoeffter P, Palacios JM, Hoyer D (June 1988). "Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes". Naunyn-Schmiedeberg's Archives of Pharmacology. 337 (6): 595–601. doi:10.1007/bf00175783. PMID 2975354. S2CID 21344978.
Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, et al. (September 1993). "A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms". Neuron. 11 (3): 449–458. doi:10.1016/0896-6273(93)90149-l. PMID 8398139. S2CID 28729004.
Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, et al. (September 1993). "Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation". Proceedings of the National Academy of Sciences of the United States of America. 90 (18): 8547–8551. Bibcode:1993PNAS...90.8547R. doi:10.1073/pnas.90.18.8547. PMC 47394. PMID 8397408.
Perry CK, Casey AB, Felsing DE, Vemula R, Zaka M, Herrington NB, et al. (February 2020). "Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT_1A and 5-HT₇ G protein-coupled receptor affinity, 3D-QSAR and molecular modeling". Bioorganic & Medicinal Chemistry. 28 (3): 115262. doi:10.1016/j.bmc.2019.115262. PMID 31882369. S2CID 209498915.
Blier P, Curet O, Chaput Y, de Montigny C (July 1991). "Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission". Neuropharmacology. 30 (7): 691–701. doi:10.1016/0028-3908(91)90176-c. PMID 1681447. S2CID 44297577.
Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, et al. (March 2013). "Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors". The International Journal of Neuropsychopharmacology. 16 (2): 445–458. doi:10.1017/S1461145712000661. PMC 5100812. PMID 22827916.
Tunnicliff G (September 1991). "Molecular basis of buspirone's anxiolytic action". Pharmacology & Toxicology. 69 (3): 149–156. doi:10.1111/j.1600-0773.1991.tb01289.x. PMID 1796057.
Zuideveld KP, Rusiç-Pavletiç J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M (December 2002). "Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats". The Journal of Pharmacology and Experimental Therapeutics. 303 (3): 1130–1137. doi:10.1124/jpet.102.036798. PMID 12438536. S2CID 14139919.
Fava M (2007). "The combination of buspirone and bupropion in the treatment of depression". Psychotherapy and Psychosomatics. 76 (5): 311–312. doi:10.1159/000104708. PMID 17700052. S2CID 46284917.
Zhu Y, Chen G, Zhang K, Chen C, Chen W, Zhu M, et al. (November 2022). "High-Throughput Metabolic Soft-Spot Identification in Liver Microsomes by LC/UV/MS: Application of a Single Variable Incubation Time Approach". Molecules. 27 (22): 8058. doi:10.3390/molecules27228058. PMC 9693510. PMID 36432161.
Zhu Y, Chen G, Zhang K, Chen C, Chen W, Zhu M, et al. (November 2022). "High-Throughput Metabolic Soft-Spot Identification in Liver Microsomes by LC/UV/MS: Application of a Single Variable Incubation Time Approach". Molecules. 27 (22): 8058. doi:10.3390/molecules27228058. PMC 9693510. PMID 36432161.
Dockens RC, Salazar DE, Fulmor IE, Wehling M, Arnold ME, Croop R (November 2006). "Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range". Journal of Clinical Pharmacology. 46 (11): 1308–1312. doi:10.1177/0091270006292250. PMID 17050795. S2CID 25050964.
Taylor DP, Moon SL (July 1991). "Buspirone and related compounds as alternative anxiolytics". Neuropeptides. 19 (Suppl): 15–19. doi:10.1016/0143-4179(91)90078-w. PMID 1679210. S2CID 13730683.
Yevich JP, Temple DL, New JS, Taylor DP, Riblet LA (February 1983). "Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives". Journal of Medicinal Chemistry. 26 (2): 194–203. doi:10.1021/jm00356a014. PMID 6131130. S2CID 28619843.
Cybulski J, Chilmonczyk Z, Szelejewski W, Wojtasiewicz K, Wróbel JT (1992). "An Efficient Synthesis of Buspirone and its Analogues". Archiv der Pharmazie. 325 (5): 313–315. doi:10.1002/ardp.19923250513. S2CID 83676454.
Kuo DL (1993). "Pd(0)-catalysed Synthesis of Buspirone and Gepirone". Heterocycles. 36 (7): 1463–1469. doi:10.3987/COM-93-6357.
Mou J, Zong ZM, Wei XY (August 2008). "Facile Synthesis of Anxiolytic Buspirone". Organic Preparations and Procedures International. 40 (4): 391–394. doi:10.1080/00304940809458099. eISSN 1945-5453. ISSN 0030-4948. S2CID 95124245.
Allen LE, Ferguson HC, Kissel JW (May 1972). "Psychosedative agents. 2. 8-(4-Substituted 1-piperazinylalkyl)-8-azaspiro(4.5)decane-7,9-diones". Journal of Medicinal Chemistry. 15 (5): 477–479. doi:10.1021/jm00275a009. PMID 5035267.

drugs.com

"Buspirone Hydrochloride Monograph for Professionals". Drugs.com.
"Buspirone Pregnancy and Breastfeeding Warnings". Drugs.com.
"Buspirone monograph". Drugs.com. Retrieved 27 August 2011.
"Buspirone". Drugs.com.

espacenet.com

worldwide.espacenet.com

US 3907801, Wu YH, Rayburn JW, issued 1975, assigned to Mead Johnson
US 3976776, Wu YH, Rayburn JW, issued 1976, assigned to Mead Johnson
US 4810789, Behme RJ, Kensler TT, Mikolasek DG, issued 1989, assigned to Bristol Myers
US 4182763, Casten GP, McKinney GR, Newton RE, Tompkins EC, Weikel Jr JH, "Buspirone anti-anxiety method", published 1980-01-08, assigned to Mead Johnson & Co. and Bristol-Meyers Co.
US 3907801, Hua WY, Warren RJ, "N-[(4-pyridyl-piperazino)-alkyl]-azaspiroalkanediones", published 1975-09-23, assigned to Mead_Johnson

fda.gov

accessdata.fda.gov

"Approval Type-1 New Molecular Entry" (PDF). United States Federal Drug Administration. 9 September 1986.
"Drugs@FDA: FDA Approved Drug Products". Food and Drug Administration.

federalregister.gov

"Determination That BUSPAR (Buspirone Hydrochloride) Tablets, 10 Milligrams, 15 Milligrams, and 30 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness". Federal Register. 19 October 2010. Retrieved 20 September 2019.

harvard.edu

ui.adsabs.harvard.edu

Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, et al. (September 1993). "Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation". Proceedings of the National Academy of Sciences of the United States of America. 90 (18): 8547–8551. Bibcode:1993PNAS...90.8547R. doi:10.1073/pnas.90.18.8547. PMC 47394. PMID 8397408.

in.gov.br

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

medicines.org.uk

"Buspirone 10mg Tablets". electronic Medicines Compendium. Actavis UK Ltd. 10 September 2012. Archived from the original on 13 November 2013. Retrieved 14 November 2013.

medscape.com

reference.medscape.com

"buspirone (Rx) - BuSpar, Buspirex, more." Medscape Reference. WebMD. Retrieved 14 November 2013.

nih.gov

pubmed.ncbi.nlm.nih.gov

Loane C, Politis M (June 2012). "Buspirone: what is it all about?". Brain Research. 1461: 111–118. doi:10.1016/j.brainres.2012.04.032. PMID 22608068. S2CID 11734819.
Gammans RE, Mayol RF, LaBudde JA (March 1986). "Metabolism and disposition of buspirone". The American Journal of Medicine. 80 (3B): 41–51. doi:10.1016/0002-9343(86)90331-1. PMID 3515929.
Wong H, Dockens RC, Pajor L, Yeola S, Grace JE, Stark AD, et al. (August 2007). "6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats". Drug Metabolism and Disposition. 35 (8): 1387–1392. doi:10.1124/dmd.107.015768. PMID 17494642. S2CID 25558546.
Mahmood I, Sahajwalla C (April 1999). "Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug". Clinical Pharmacokinetics. 36 (4): 277–287. doi:10.2165/00003088-199936040-00003. PMID 10320950. S2CID 1102318.
Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, et al. (April 2005). "Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes". Drug Metabolism and Disposition. 33 (4): 500–507. doi:10.1124/dmd.104.000836. PMID 15640381. S2CID 10142905.
Wilson TK, Tripp J (January 2018). "Buspirone". StatPearls. PMID 30285372.
Howland RH (November 2015). "Buspirone: Back to the Future". Journal of Psychosocial Nursing and Mental Health Services. 53 (11): 21–24. doi:10.3928/02793695-20151022-01. PMID 26535760.
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clinic Proceedings. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.
Trinchieri M, Trinchieri M, Perletti G, Magri V, Stamatiou K, Cai T, et al. (August 2021). "Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review". The Journal of Sexual Medicine. 18 (8): 1354–1363. doi:10.1016/j.jsxm.2021.05.016. PMID 34247952. S2CID 235798526. Buspirone, a non-benzodiazepine anxiolytic, have even demonstrated enhancement of sexual function in certain individuals. For this reason, they have been proposed as augmentation agents (antidotes) or substitution agents in patients with emerging sexual dysfunction after treatment with antidepressants.
Montejo AL, Prieto N, de Alarcón R, Casado-Espada N, de la Iglesia J, Montejo L (October 2019). "Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach". Journal of Clinical Medicine. 8 (10): 1640. doi:10.3390/jcm8101640. PMC 6832699. PMID 31591339.
Sontheimer DL, Ables AZ (March 2001). "Is imipramine or buspirone treatment effective in patients wishing to discontinue long-term benzodiazepine use?". The Journal of Family Practice. 50 (3): 203. PMID 11252203.
Garrett AR, Hawley JS (April 2018). "SSRI-associated bruxism: A systematic review of published case reports". Neurology. Clinical Practice. 8 (2): 135–141. doi:10.1212/CPJ.0000000000000433. PMC 5914744. PMID 29708207.
Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ (December 1998). "Grapefruit juice substantially increases plasma concentrations of buspirone". Clinical Pharmacology and Therapeutics. 64 (6): 655–660. doi:10.1016/S0009-9236(98)90056-X. PMID 9871430. S2CID 22009095.
Lamberg TS, Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ (1998). "The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone". European Journal of Clinical Pharmacology. 54 (9–10): 761–766. doi:10.1007/s002280050548. PMID 9923581. S2CID 21939719.
Boess FG, Martin IL (1994). "Molecular biology of 5-HT receptors". Neuropharmacology. 33 (3–4): 275–317. doi:10.1016/0028-3908(94)90059-0. PMID 7984267. S2CID 35553281.
Sato H, Skelin I, Diksic M (July 2010). "Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study". Brain Research. 1345: 28–44. doi:10.1016/j.brainres.2010.05.054. PMID 20501324. S2CID 22979155.
Hamik A, Oksenberg D, Fischette C, Peroutka SJ (July 1990). "Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites". Biological Psychiatry. 28 (2): 99–109. doi:10.1016/0006-3223(90)90627-e. PMID 1974152. S2CID 25608914.
Peroutka SJ, Switzer JA, Hamik A (1989). "Identification of 5-hydroxytryptamine1D binding sites in human brain membranes". Synapse. 3 (1): 61–66. doi:10.1002/syn.890030109. PMID 2521959. S2CID 23503235.
Waeber C, Schoeffter P, Palacios JM, Hoyer D (June 1988). "Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes". Naunyn-Schmiedeberg's Archives of Pharmacology. 337 (6): 595–601. doi:10.1007/bf00175783. PMID 2975354. S2CID 21344978.
Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, et al. (September 1993). "A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms". Neuron. 11 (3): 449–458. doi:10.1016/0896-6273(93)90149-l. PMID 8398139. S2CID 28729004.
Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, et al. (September 1993). "Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation". Proceedings of the National Academy of Sciences of the United States of America. 90 (18): 8547–8551. Bibcode:1993PNAS...90.8547R. doi:10.1073/pnas.90.18.8547. PMC 47394. PMID 8397408.
Perry CK, Casey AB, Felsing DE, Vemula R, Zaka M, Herrington NB, et al. (February 2020). "Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT_1A and 5-HT₇ G protein-coupled receptor affinity, 3D-QSAR and molecular modeling". Bioorganic & Medicinal Chemistry. 28 (3): 115262. doi:10.1016/j.bmc.2019.115262. PMID 31882369. S2CID 209498915.
Blier P, Curet O, Chaput Y, de Montigny C (July 1991). "Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission". Neuropharmacology. 30 (7): 691–701. doi:10.1016/0028-3908(91)90176-c. PMID 1681447. S2CID 44297577.
Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, et al. (March 2013). "Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors". The International Journal of Neuropsychopharmacology. 16 (2): 445–458. doi:10.1017/S1461145712000661. PMC 5100812. PMID 22827916.
Tunnicliff G (September 1991). "Molecular basis of buspirone's anxiolytic action". Pharmacology & Toxicology. 69 (3): 149–156. doi:10.1111/j.1600-0773.1991.tb01289.x. PMID 1796057.
Zuideveld KP, Rusiç-Pavletiç J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M (December 2002). "Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats". The Journal of Pharmacology and Experimental Therapeutics. 303 (3): 1130–1137. doi:10.1124/jpet.102.036798. PMID 12438536. S2CID 14139919.
Fava M (2007). "The combination of buspirone and bupropion in the treatment of depression". Psychotherapy and Psychosomatics. 76 (5): 311–312. doi:10.1159/000104708. PMID 17700052. S2CID 46284917.
Zhu Y, Chen G, Zhang K, Chen C, Chen W, Zhu M, et al. (November 2022). "High-Throughput Metabolic Soft-Spot Identification in Liver Microsomes by LC/UV/MS: Application of a Single Variable Incubation Time Approach". Molecules. 27 (22): 8058. doi:10.3390/molecules27228058. PMC 9693510. PMID 36432161.
Zhu Y, Chen G, Zhang K, Chen C, Chen W, Zhu M, et al. (November 2022). "High-Throughput Metabolic Soft-Spot Identification in Liver Microsomes by LC/UV/MS: Application of a Single Variable Incubation Time Approach". Molecules. 27 (22): 8058. doi:10.3390/molecules27228058. PMC 9693510. PMID 36432161.
Dockens RC, Salazar DE, Fulmor IE, Wehling M, Arnold ME, Croop R (November 2006). "Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range". Journal of Clinical Pharmacology. 46 (11): 1308–1312. doi:10.1177/0091270006292250. PMID 17050795. S2CID 25050964.
Jajoo HK, Mayol RF, LaBudde JA, Blair IA (1989). "Metabolism of the antianxiety drug buspirone in human subjects". Drug Metabolism and Disposition. 17 (6): 634–640. PMID 2575499.
Taylor DP, Moon SL (July 1991). "Buspirone and related compounds as alternative anxiolytics". Neuropeptides. 19 (Suppl): 15–19. doi:10.1016/0143-4179(91)90078-w. PMID 1679210. S2CID 13730683.
Yevich JP, Temple DL, New JS, Taylor DP, Riblet LA (February 1983). "Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives". Journal of Medicinal Chemistry. 26 (2): 194–203. doi:10.1021/jm00356a014. PMID 6131130. S2CID 28619843.
Allen LE, Ferguson HC, Kissel JW (May 1972). "Psychosedative agents. 2. 8-(4-Substituted 1-piperazinylalkyl)-8-azaspiro(4.5)decane-7,9-diones". Journal of Medicinal Chemistry. 15 (5): 477–479. doi:10.1021/jm00275a009. PMID 5035267.

ncbi.nlm.nih.gov

Wilson TK, Tripp J (January 2018). "Buspirone". StatPearls. PMID 30285372.
Montejo AL, Prieto N, de Alarcón R, Casado-Espada N, de la Iglesia J, Montejo L (October 2019). "Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach". Journal of Clinical Medicine. 8 (10): 1640. doi:10.3390/jcm8101640. PMC 6832699. PMID 31591339.
Garrett AR, Hawley JS (April 2018). "SSRI-associated bruxism: A systematic review of published case reports". Neurology. Clinical Practice. 8 (2): 135–141. doi:10.1212/CPJ.0000000000000433. PMC 5914744. PMID 29708207.
Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, et al. (September 1993). "Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation". Proceedings of the National Academy of Sciences of the United States of America. 90 (18): 8547–8551. Bibcode:1993PNAS...90.8547R. doi:10.1073/pnas.90.18.8547. PMC 47394. PMID 8397408.
Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, et al. (March 2013). "Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors". The International Journal of Neuropsychopharmacology. 16 (2): 445–458. doi:10.1017/S1461145712000661. PMC 5100812. PMID 22827916.
Zhu Y, Chen G, Zhang K, Chen C, Chen W, Zhu M, et al. (November 2022). "High-Throughput Metabolic Soft-Spot Identification in Liver Microsomes by LC/UV/MS: Application of a Single Variable Incubation Time Approach". Molecules. 27 (22): 8058. doi:10.3390/molecules27228058. PMC 9693510. PMID 36432161.
Zhu Y, Chen G, Zhang K, Chen C, Chen W, Zhu M, et al. (November 2022). "High-Throughput Metabolic Soft-Spot Identification in Liver Microsomes by LC/UV/MS: Application of a Single Variable Incubation Time Approach". Molecules. 27 (22): 8058. doi:10.3390/molecules27228058. PMC 9693510. PMID 36432161.

dailymed.nlm.nih.gov

"BUSPIRONE HCL (buspirone hydrochloride) tablet [Watson Laboratories, Inc.]". DailyMed. Watson Laboratories, Inc. July 2013. Retrieved 14 November 2013.

patents.google.com

DE2057845 idem Y Wu, J Rayburn, U.S. patent 3,717,634 (1973 to Mead Johnson).

semanticscholar.org

api.semanticscholar.org

Loane C, Politis M (June 2012). "Buspirone: what is it all about?". Brain Research. 1461: 111–118. doi:10.1016/j.brainres.2012.04.032. PMID 22608068. S2CID 11734819.
Wong H, Dockens RC, Pajor L, Yeola S, Grace JE, Stark AD, et al. (August 2007). "6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats". Drug Metabolism and Disposition. 35 (8): 1387–1392. doi:10.1124/dmd.107.015768. PMID 17494642. S2CID 25558546.
Mahmood I, Sahajwalla C (April 1999). "Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug". Clinical Pharmacokinetics. 36 (4): 277–287. doi:10.2165/00003088-199936040-00003. PMID 10320950. S2CID 1102318.
Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, et al. (April 2005). "Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes". Drug Metabolism and Disposition. 33 (4): 500–507. doi:10.1124/dmd.104.000836. PMID 15640381. S2CID 10142905.
Trinchieri M, Trinchieri M, Perletti G, Magri V, Stamatiou K, Cai T, et al. (August 2021). "Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review". The Journal of Sexual Medicine. 18 (8): 1354–1363. doi:10.1016/j.jsxm.2021.05.016. PMID 34247952. S2CID 235798526. Buspirone, a non-benzodiazepine anxiolytic, have even demonstrated enhancement of sexual function in certain individuals. For this reason, they have been proposed as augmentation agents (antidotes) or substitution agents in patients with emerging sexual dysfunction after treatment with antidepressants.
Prisco V, Iannaccone T, Di Grezia G (1 April 2017). "Use of buspirone in selective serotonin reuptake inhibitor-induced sleep bruxism". European Psychiatry. Abstract of the 25th European Congress of Psychiatry. 41: S855. doi:10.1016/j.eurpsy.2017.01.1701. S2CID 148816505.
Fulton B, Brogden RN (1997). "Buspirone". CNS Drugs. 7 (1): 68–88. doi:10.2165/00023210-199707010-00007. ISSN 1172-7047. S2CID 57668523.
Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ (December 1998). "Grapefruit juice substantially increases plasma concentrations of buspirone". Clinical Pharmacology and Therapeutics. 64 (6): 655–660. doi:10.1016/S0009-9236(98)90056-X. PMID 9871430. S2CID 22009095.
Lamberg TS, Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ (1998). "The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone". European Journal of Clinical Pharmacology. 54 (9–10): 761–766. doi:10.1007/s002280050548. PMID 9923581. S2CID 21939719.
Boess FG, Martin IL (1994). "Molecular biology of 5-HT receptors". Neuropharmacology. 33 (3–4): 275–317. doi:10.1016/0028-3908(94)90059-0. PMID 7984267. S2CID 35553281.
Sato H, Skelin I, Diksic M (July 2010). "Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study". Brain Research. 1345: 28–44. doi:10.1016/j.brainres.2010.05.054. PMID 20501324. S2CID 22979155.
Hamik A, Oksenberg D, Fischette C, Peroutka SJ (July 1990). "Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites". Biological Psychiatry. 28 (2): 99–109. doi:10.1016/0006-3223(90)90627-e. PMID 1974152. S2CID 25608914.
Peroutka SJ, Switzer JA, Hamik A (1989). "Identification of 5-hydroxytryptamine1D binding sites in human brain membranes". Synapse. 3 (1): 61–66. doi:10.1002/syn.890030109. PMID 2521959. S2CID 23503235.
Waeber C, Schoeffter P, Palacios JM, Hoyer D (June 1988). "Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes". Naunyn-Schmiedeberg's Archives of Pharmacology. 337 (6): 595–601. doi:10.1007/bf00175783. PMID 2975354. S2CID 21344978.
Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, et al. (September 1993). "A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms". Neuron. 11 (3): 449–458. doi:10.1016/0896-6273(93)90149-l. PMID 8398139. S2CID 28729004.
Perry CK, Casey AB, Felsing DE, Vemula R, Zaka M, Herrington NB, et al. (February 2020). "Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT_1A and 5-HT₇ G protein-coupled receptor affinity, 3D-QSAR and molecular modeling". Bioorganic & Medicinal Chemistry. 28 (3): 115262. doi:10.1016/j.bmc.2019.115262. PMID 31882369. S2CID 209498915.
Blier P, Curet O, Chaput Y, de Montigny C (July 1991). "Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission". Neuropharmacology. 30 (7): 691–701. doi:10.1016/0028-3908(91)90176-c. PMID 1681447. S2CID 44297577.
Zuideveld KP, Rusiç-Pavletiç J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M (December 2002). "Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats". The Journal of Pharmacology and Experimental Therapeutics. 303 (3): 1130–1137. doi:10.1124/jpet.102.036798. PMID 12438536. S2CID 14139919.
Fava M (2007). "The combination of buspirone and bupropion in the treatment of depression". Psychotherapy and Psychosomatics. 76 (5): 311–312. doi:10.1159/000104708. PMID 17700052. S2CID 46284917.
Dockens RC, Salazar DE, Fulmor IE, Wehling M, Arnold ME, Croop R (November 2006). "Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range". Journal of Clinical Pharmacology. 46 (11): 1308–1312. doi:10.1177/0091270006292250. PMID 17050795. S2CID 25050964.
Taylor DP, Moon SL (July 1991). "Buspirone and related compounds as alternative anxiolytics". Neuropeptides. 19 (Suppl): 15–19. doi:10.1016/0143-4179(91)90078-w. PMID 1679210. S2CID 13730683.
Yevich JP, Temple DL, New JS, Taylor DP, Riblet LA (February 1983). "Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives". Journal of Medicinal Chemistry. 26 (2): 194–203. doi:10.1021/jm00356a014. PMID 6131130. S2CID 28619843.
Cybulski J, Chilmonczyk Z, Szelejewski W, Wojtasiewicz K, Wróbel JT (1992). "An Efficient Synthesis of Buspirone and its Analogues". Archiv der Pharmazie. 325 (5): 313–315. doi:10.1002/ardp.19923250513. S2CID 83676454.
Mou J, Zong ZM, Wei XY (August 2008). "Facile Synthesis of Anxiolytic Buspirone". Organic Preparations and Procedures International. 40 (4): 391–394. doi:10.1080/00304940809458099. eISSN 1945-5453. ISSN 0030-4948. S2CID 95124245.

tga.gov.au

ebs.tga.gov.au

"BUSPAR® (buspirone hydrochloride) Tablets 5 mg & 10 mg PRODUCT INFORMATION" (PDF). TGA eBusiness Services. Aspen Pharma Pty Ltd. January 2010. Retrieved 14 November 2013.

unc.edu

pdsp.unc.edu

Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.

web.archive.org

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Buspirone 10mg Tablets". electronic Medicines Compendium. Actavis UK Ltd. 10 September 2012. Archived from the original on 13 November 2013. Retrieved 14 November 2013.

worldcat.org

Fulton B, Brogden RN (1997). "Buspirone". CNS Drugs. 7 (1): 68–88. doi:10.2165/00023210-199707010-00007. ISSN 1172-7047. S2CID 57668523.
Mou J, Zong ZM, Wei XY (August 2008). "Facile Synthesis of Anxiolytic Buspirone". Organic Preparations and Procedures International. 40 (4): 391–394. doi:10.1080/00304940809458099. eISSN 1945-5453. ISSN 0030-4948. S2CID 95124245.

zenodo.org

Mahmood I, Sahajwalla C (April 1999). "Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug". Clinical Pharmacokinetics. 36 (4): 277–287. doi:10.2165/00003088-199936040-00003. PMID 10320950. S2CID 1102318.